Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIUMPH Trial for Nocturnal Urinary Symptoms
NCT07829029Phase 4Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Oct 2022
- Primary completion
- May 2027
- Countries
- 1
01
Overview
A Phase 4 trial of tolterodine, mirabegron in nocturia, urinary incontinence (UI), sponsored by University of California, San Francisco. Started Oct 2022; status: recruiting.
02
Drugs
tolterodinemirabegron
03
Conditions
nocturiaurinary incontinence (UI)
Beyond the preview
Go deeper on NCT07829029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07829029.